Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03781063
Title Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Sermonix Pharmaceuticals LLC
Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.